Explore the words cloud of the IC2PerMed project. It provides you a very rough idea of what is the project "IC2PerMed" about.
The following table provides information about the project.
Coordinator |
UNIVERSITA CATTOLICA DEL SACRO CUORE
Organization address contact info |
Coordinator Country | Italy [IT] |
Total cost | 2˙135˙187 € |
EC max contribution | 1˙691˙437 € (79%) |
Programme |
1. H2020-EU.3.1.6. (Health care provision and integrated care) |
Code Call | H2020-SC1-2019-Single-Stage-RTD |
Funding Scheme | CSA |
Starting year | 2020 |
Duration (year-month-day) | from 2020-01-01 to 2023-12-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | UNIVERSITA CATTOLICA DEL SACRO CUORE | IT (MILANO) | coordinator | 405˙125.00 |
2 | INNO TSD | FR (SOPHIA ANTIPOLIS VALBONNE) | participant | 356˙625.00 |
3 | STEINBEIS 2I GMBH | DE (STUTTGART) | participant | 334˙687.00 |
4 | FONDAZIONE TELETHON | IT (ROMA) | participant | 250˙937.00 |
5 | BIOBANKS AND BIOMOLECULAR RESOURCESRESEARCH INFRASTRUCTURE CONSORTIUM(BBMRI-ERIC) | AT (GRAZ) | participant | 219˙687.00 |
6 | WORLD FEDERATION OF PUBLIC HEALTH ASSOCIATIONS | CH (GENEVA) | participant | 124˙375.00 |
7 | BGI SHENZHEN LIFE SCIENCE RESEARCH INSTITUTION | CN (SHENZHEN) | participant | 0.00 |
8 | CANCER HOSPITAL OF CHINESE ACADEMYOF MEDICAL SCIENCES | CN (BEIJING) | participant | 0.00 |
9 | TSINGHUA UNIVERSITY | CN (BEIJING) | participant | 0.00 |
Personalised Medicine (PM) approaches, thanks to the latest technological advances notably in the fields of biomedical and digital technologies, prove their potential to improve healthcare and underpin more efficient and sustainable health systems. PM is at the top of the European Commission research agenda, with funding devoted to projects along the entire value chain. In China, PM is attracting massive interest, with the government capitalising on its expertise in biotechnology, computing hardware and the ability to put in place the infrastructures for supporting large bioinformatics projects. Turning PM into an opportunity for all citizens and patients requires the engagement of all stakeholders, in order to define common research and development approaches, standards, and priorities, and to scale up the collaboration at the International level. In order to respond to these challenges, the EU supports actions developed within the International Consortium for Personalised Medicine (ICPerMed). IC2PerMed project will provide key solutions for enabling the convergence under ICPerMed consortium of European and Chinese stakeholders towards a common approach of PM research, innovation, development and implementation involving policy makers and healthcare beneficiaries, by: - mapping policies, programmes, standards and initiatives related to PM in Europe in China for identifying the opportunities for research collaborations; - structuring its developments upon an ecosystem of European and Chinese experts, collaborating in Working Groups centred on ICPerMed Action plan priorities; - setting bridges with key organisms involved in the definition and implementation of PM and healthcare systems in both economic areas, both on benefits for coordinated approaches for research and on concrete developments taking place within and along the project; - inserting its developments in international contexts, through ICPerMed and its involvement in relevant initiatives and networks.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IC2PERMED" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IC2PERMED" are provided by the European Opendata Portal: CORDIS opendata.